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Abstract:  Development of biopharmaceuticals is a challenging issue in bioethics. Unlike 
conventional, small molecular weight drugs, biopharmaceuticals are proteins derived from 
DNA technology and hybrid techniques with complex three dimensional structures. Immu-
nogenicity of biopharmaceuticals should always be tested in clinical settings due to low 
predictive value of preclinical animal models. However, non-human primates (NHP) and 
transgenic mice could be used to address certain aspects of immunogenicity. Substantial 
efforts have been made to reduce NHP use in biopharmaceutical drug development, e.g. 
study design improvements and changes in regulatory policy. In addition, several expert 
groups are active in this field (e.g. NC3Rs, BioSafe, and Biopharmaceutical Technical Group). 
Despite that, there is an increasing trend of use of NHP in preclinical safety testing of bi-
opharmaceuticals, especially regarding monoclonal antibodies. Other potential bioethi-
cal issues related biopharmaceutical drug development are their cost/effectiveness ratio, 
clinical safety assessment, production of biosimilars, and comparison of their efficacy with 
placebo in countries without intention to market. Identification of the human genome has 
opened many new bioethical issues. Development of biopharmaceuticals is an important 
bioethical issue for several reasons. It connects all aspects of contemporary bioethics: bio-
medicine (e.g. clinical trials in vulnerable subjects), animal welfare and the most recent ad-
vances in biotechnology. In particular, biopharmaceutical drug development is a challeng-
ing issue regarding treatment of rare diseases.
Key words:  bioethics, biopharmaceutics, drug development, immunogenicity, animal 
welfare, non-human primates.
1. Introduction
According to a widely accepted definition, bioethics is the philosophical study 
of the ethical controversies brought about by advances in biology and medicine, 
for example the Human Genome Project and recent door opening to biosimilars 
in the EU and US. The concept of integrative bioethics offers us a vision of hu-
man scientific and technological development more humane than what occurs in 
Borislav Pekić’s novel “1999”1. 
1   The novel describes search for humanness that had disappeared from Earth long ago 
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According to Tom Beauchamp, contemporary bioethics has both theoretical and 
practical background (Beauchamp 2004: 209). The first corresponds to the philo-
sophical ethical theory, and the other is closer to the problems that are encoun-
tered in medical practice. At the same time, Beauchamp predicted a “divorce” be-
tween the two approaches. Fortunately, he was wrong at least due to the emerging 
challenges in biomedical practice. Recent advances in medicine and biology have 
opened the Pandora’s box and brought numerous controversial issues that require 
a pluriperspective approach, inherent to integrated bioethics2.
2. Bioethics, corporate ethics and biopharmaceuticals
There are various bioethical issues related to the production of biopharmaceuti-
cals (biotech drugs), their testing and use. In general, management of pharma-
ceutical companies is willing to actively promote/support ethical aspects of drug 
development and use because lapses in corporate ethical conduct lead to inevita-
ble loss of public trust (Eaton 2007: 39). (Bio)ethics is tightly interconnected with 
drug development processes due to the intrinsic nature of drug products (life/
death; health/disability), and because drugs are studied both on animals and hu-
mans. There are several aspects of ethics in pharmaceutical industry: business 
ethics, ethical social behavior and ethical drug development (Fournel 2005: 33). 
The first aspect involves, for example, commercial activities, contracts, pricing, 
incentives and kickbacks. At this level, there are different control mechanisms 
(at least self-regulation, legislation and consumer advocacy) that would mitigate 
unethical conduct of a business. However, unethical behavior of pharmaceutical 
companies may involve more subtle mechanism, for example insufficient open-
ness of information sharing, and risk mitigation for patients. Finally, there is a 
wide spectrum of bioethical issues across the drug development continuum: use 
of patients in countries without intention to market, inadequate trial design, dif-
ferent safety standards etc. 
Access to medicine is a human right as part of the right to health. It was estab-
lished as a social right in the WHO Constitution (1946), and in the Universal 
Declaration of Human Rights (1948) by the World Health Organization. Rational 
drug therapy involves the assessment of a drug’s efficacy, safety, quality and cost 
(Todorović 2012a: 28). Biopharmaceuticals are often highly effective in the treat-
ment of serious disorders accompanied with high mortality and/or chronic dis-
ability. However, their safety is usually confirmed in a limited number of animal 
models and a small number of patients. Long patent protection prevents other 
2   Contemporary bioethics has evolved through different phases, from a social movement 
focused on practical medical problems and principalism of the 1970s and 1980s to its current 
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manufacturers to make cheaper copies of these drugs3. In developing countries, 
the problem of the availability of biopharmaceuticals is due to several factors: 
their cost, patent protection, regulatory constraints and scientific and technologi-
cal capacity (Scherer 2011).
Biological therapeutics (vaccines, blood derivatives, biotech drugs/biopharma-
ceuticals, and other products extracted from native, non-engineered biological 
sources) are large molecules that differ substantially from the conventional chem-
ical entities. Usually, biological drugs are complex protein products of living tis-
sues, supposed to be identical to human molecules. Accordingly, it is very difficult 
to copy them in different laboratories. Biopharmaceuticals are the most complex 
biological drugs. They are produced by recombinant DNA technology, which is 
a very expensive and time consuming process. Biotech companies have a unique 
position in the market due to the cost of their products and potential earnings 
(see below).
A small number of biotech drugs may be copied or produced by other pharmaceu-
tical companies. These copies are called “biologically similar drugs” or “biosimi-
lars” in EU, “follow-on pharmaceuticals” in the USA and Japan, “subsequent entry 
biologics” in Canada and “biocomparables” in Mexico. Copies are never complete-
ly identical to the original (“twins but not clones”), so it is necessary to test them 
in clinical studies before the approval. This process is much more complicated 
than making a copy of the simple chemical drugs. Cost of clinical trials of biosim-
ilars is high, and they may last more than a decade.
3. The cost of biopharmaceutical research and development
The real cost of drug research and development (R&D) seems to be a controversial 
issue. For example, DiMasi et al. estimated that total cost of R&D of a new drug 
could exceed 800 million US dollars, which was two to four times higher than in 
other reports on that matter (DiMasi et al. 2003: 151). Their publication was based 
on confidential reports  from pharmaceutical companies.  New estimates were 
even higher, reaching 1,8 billion of US dollars per new drug (Light and Warbur-
ton 2005: 1030; Paul and Mytelka 2010: 203). The annual raise in R&D costs per ap-
proved biopharmaceutical molecule has reached 7% (Scherer 2011). It seems that 
3   Drug patent protection in the U.S. lasts 20 years. However, pharmaceutical companies ap-
ply for patent protection before the drug is clinically tested and before it reaches the market. 
Actually, the real patent protects the first manufacturer of the drug between 8 to 10 years. 
When the patent expires, it is possible to make and sell copies of the original drug (origina-
tor brand) called generic drugs (short: generics). Their production is much cheaper, and the 
manufacturer is only required to confirm that generics contain the same active ingredients as 
the original/reference drug. In addition, generics should be tested for bioequivalence, i.e. the 
same part/percent of the dose administered should reach the target tissue compared to the 
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pharmaceutical companies tend to exaggerate the total cost of drug R&D in order 
to justify their products’ high prices. Such a trend is mainly due to rapidly increas-
ing number of clinical trials of new drugs. The clinical R&D cost has increased 
more than fifty times during last 50 years (Scherer 2011)! In particular, it has be-
come more difficult for pharmaceutical companies to prove that their products 
are better than those already on the market, not just due to tougher regulation/
standards. 
The second parameter that should be taken into account is the relative market 
share of biotech companies. According to Cavalla and Minhas, the biotech sec-
tor is under constant pressure to develop more biopharmaceuticals due to their 
economic shortcomings (Cavalla and Minhas 2010: 230). Namely, they are perma-
nently between the “Scilla” of the highest expectations/future promise and poten-
tial (indicated by “price/earnings ratio”) and the “Charybdis” of the lowest current 
earnings (indicated by “return on capital”) compared to large pharma and gener-
ic pharmaceutic companies. There are different implications of such a trend: in-
creasing use of non-human primates in preclinical biopharmaceutical drug de-
velopment, changes in legislation that would abbreviate approval pathway for 
biosimilars, safety concerns regarding biopharmaceutical drug development and 
use, clinical trials of anticancer biotech drugs etc. 
4. “Of mice and men”: preclinical evaluation 
of biopharmaceuticals 
Use of non-human primates (NHPs) in preclinical development of biopharma-
ceuticals raises public concerns. There is a long-term debate on that matter and 
a single conclusion could not be reached (see Nuffield Council on Bioethics con-
clusions on animal experimentation) (Perry 2007: 42). Animal liberation asso-
ciations strongly oppose the use of NHPs in drug R&D, while pharmaceutical 
companies even argue that some NHPs could be found mainly in their breed-
ing establishments, but not in the wild; also, they state that NHPs welfare is not 
significantly impaired in such establishments. In addition, replacement of NHPs 
with lower species is in agreement with 3R principles (Russell and Birch 1959; 
Todorović and Vučinić 2010), but neuroscientists state that their investigation is 
not possible without in vivo models close to humans (Abbott 2010: 964). Final-
ly, experiments in NHPs are still considered to be “necessary in scientific pro-
cedures” in the Directive 2010/63/EU preamble (paragraph 17). An unresolved 
question is whether it is morally “worse” to use NHPs instead of lower species, 
e.g. dogs or mice, because there is a human prejudice for species physically more 
like ourselves. In other words, whether our lack of understanding of the mental 
lives of animals that are different from us could influence our decision regarding 
in vivo experiments. Number of NHPs used in biopharmaceutical drug develop-
ment could be reduced in different ways: for example, refinement of experimental COnTeMPOrarY IssUes In BIOeThICs: The naTIOnal anD reGIOnal COnTeXT
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  design, and replacement of NHPs with lower species (e.g. transgenic mice) or the 
appropriate validated alternatives. However, such in vivo models are still inevita-
ble in preclinical immunogenicity testing of new biopharmaceuticals. According 
to Chapman et al., NHPs still remain the only relevant species for for preclinical 
safety testing of monoclonal antibodies (mAbs), and there is an increasing num-
ber of mAbs entering clinical trials (Chapman et al. 2009: 505). Accordingly, the 
trend of use of NHPs in preclinical testing of those biopharmaceuticals is actu-
ally increasing. The most important argument for and against the use of NHPs in 
preclinical drug testing is the same: they are close to humans. However, Baily op-
poses the use of NHPs in drug R&D as an “irrelevant, unnecessary, even hazard-
ous to human health” having “little or no predictive value or application to human 
medicine” (Baily 2005: 235). 
5. Legislation regarding biopharmaceutical medicine
Another controversial bioethics issues regarding biopharmaceuticals are chang-
es in legislation that shorten approval pathways for biosimilars (generic versions 
of biopharmaceutics). Until recently, biosimilars were expected to pass more ex-
tensive (and more expensive) preclinical and clinical testing than their chemical 
counterparts. The first drug that was approved in the EU in accordance with the 
Directives 2001/83/EC and 2004/27/EC after such a complex procedure was Om-
nitrope®, Sandoz. Recent changes in EU and US legislation have removed barri-
ers for more rapid approval of biosimilars. It could significantly reduce the cost of 
treatment with biopharmaceutical drugs and decrease inequity in access to those 
highly efficient medicines, especially in developing countries. However, there are 
significant concerns regarding new standards for the assessment of their safety 
and efficacy. For example a copy of filgastrim, biopharmaceutical drug that stim-
ulates bone marrow cells, was tested only in healthy volunteers. In particular, the 
number of leukocytes in peripheral blood was only checked in those volunteers 
in order to test the efficacy of such a biosimilar, without confronting its clinical 
efficacy and safety with the original drug (Anonymous 2012: 686). Abbreviated 
clinical testing of biosmiliars in specific targeted small-scale clinical studies, and 
extrapolation of data from one indication to other indications for the same drug 
have replaced extensive testing. However, safety of biosimilar drugs should be 
separately tested for each indication, and such an extrapolation is not always ade-
quate (Todorović et al. 2009: 467; Todorović and Prostran 2012: 133). The principle 
of justice (equal access to medicines) should not be in contradiction with anoth-
er bioethical principle of non-maleficence (do not harm) in that particular case.
6. Safety of biopharmaceuticals
Monitoring biopharmaceutical drug safety deserves special attention. It is not the 
sole duty of pharmaceutical companies (sponsors of clinical trials) to assess such BIOeThICal IssUes In The DevelOPMenT OF BIOPharMaCeUTICals ZORAN TODOROvIć, DRAGANA PROTIć
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a complex problem. The spontaneous reporting system of suspected adverse drug 
reactions involves both health professionals and patients. In particular, there is 
a need to recruit more volunteers from both cohorts to actively take part in such 
a monitoring, and to report their observations to national drug agencies (for ex-
ample, Medicines and Medical Devices Agency of Serbia, ALIMS). Ethics in drug 
safety monitoring could be divided into two categories: individual and collective 
ethics (Palmer 1993: 219; Singer P 1981). Individual ethics assesses what is best 
for the present, individual patient; it is more suitable for rare (type B) adverse 
drug reactions and more common during early phases of clinical trials when drug 
safety is a primary endpoint. Individual ethics uses Bayesian statistical approach/
Bayesian probability theory in which sample data are real, and population data are 
only an abstraction. On the other hand, collective ethics analyzes what is best for 
the population of patients or society; it is more suitable for mild, reversible type 
A adverse drug reactions, and more common during late phases of clinical phas-
es. Collective ethics uses traditional, frequentist statistical approach, which sees 
probability as the long-run expected frequency of occurrence (in other words, 
the frequentists believe that a population mean is real but unknown, and can be 
only estimated from the sample data) (Annis, internet). The main disadvantage 
of the spontaneous reporting system of adverse drug reactions is diffusion of re-
sponsibility (“no one is responsible”), which may lead to underreporting. It might 
be overcome in different ways; we can, for example disseminate information on 
drug safety, promote education in pharmacovigilance, increase motivation and 
strengthen the responsibility of individuals to participate in such a reporting sys-
tem. In other words, we should try to overcome this “Bystander effect” of health 
professionals, i.e. to move “individual focus away from feeling uninspired by their 
diffusion of responsibility and towards individual responsibility being promoted 
in a way that makes them feel as though their combined efforts will make an ef-
fectual collective” (Beaker 2011: 1). In addition, lack of knowledge on drug safety 
and poor prescribing skills of young medical doctors should be taken into account 
(Harding 2010: 598). 
7. Conclusion
In conclusion, biopharmaceuticals are not a Panacea, and their efficacy and safety 
should be carefully weighed against their cost. However, this is a not just a phar-
macoeconomic issue. Widespread availability of biosimilars would enable more 
patients to be treated with these highly effective drugs, especially in developing 
countries, which is consistent with the bioethical principle of justice. Of course, it 
does not preclude improvement of standards in assessment of the safety of those 
complex agents.
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Bioetička pitanja u razvoju biofarmaceutika 
apstrakt
razvoj biofarmaceutika predstavlja izazov u bioetici. Za razliku od uobičajenih leko-
va male molekulske mase, biofarmaceutici su proteini kompleksne trodimenzionalne 
strukture koji se dobijaju tehnologijom rekombinantne DnK i tehnikom hibridoma. 
Imunogenost biofarmaceutika treba uvek proveriti u kliničkim studijama zbog male 
prediktivne prednosti pretkliničkih animalnih modela. Međutim, primati (izuzev čove-
ka) i transgeni sojevi miševa mogu se upotrebiti da bi se naznačili neki aspekti imuno-
genosti. Značajni napori su učinjeni u cilju smanjenja upotrebe primata u razvoju bi-
ofarmaceutika, npr. poboljšanja dizajna istraživanja i promene u zakonskoj regulativi. 
Osim toga, u ovoj oblasti su aktivne i pojedine ekspertske grupe (npr. nC3rs, Biosafe i 
Biopharmaceutical Technical Group). Uprkos tome, postoji rastući trend upotrebe pri-
mata izuzev čoveka u pretkliničkom ispitivanju bezbednosti biofarmaceutika, posebno 
kada su u pitanju monoklonska antitela. Druga bioetička pitanja koja se mogu dovesti u 
vezu sa razvojem biofarmaceutika su odnos njihove cene i efikasnosti, procena bezbed-
nosti u kliničkim uslovima, proizvodnja biološki sličnih lekova i upoređivanje njihove 
efikasnosti sa placebom u zemljama u kojima ne postoji namera o plasmanu. Upozna-
vanje humanog genoma otvorilo je mnoga bioetička pitanja. razvoj biofarmaceutika je 
važno bioetičko pitanje iz više razloga. Ono povezuje sve aspekte savremene bioetike: 
biomedicinu (npr. klinička ispitivanja na vulnerabilnim ispitanicima), dobrobit životinja 
i najnovija dostignuća u biotehnologiji. Posebno, razvoj biofarmaceutika je izazov kada 
je u pitanju lečenje retkih bolesti. 
Ključne reči  bioetika, biofarmaceutci, razvoj lekova, imunogenost, dobrobit životinja, 
primati izuzev čoveka.